Although biomarkers like a-synuclein and genetic markers (PPDyn, PPE, PTT) are highlighted for tracking DBS effects in PD, their clinical use in AD remains largely unexplored. The need for further research to develop standardized biomarker panels for evaluating DBS efficacy across different neurological conditions is emphasized.

One source mentions the use of blood-based biomarkers for identifying individuals with biological evidence of AD, primarily in clinical trial prescreening. This suggests a potential role for these biomarkers in prescreening candidates for DBS, though the focus is more on standardizing biomarker collection and analysis rather than their use in DBS decision-making.

Another source explores DBS as a treatment for AD, focusing on stimulation targets such as the fornix, nucleus basalis of Meynert (NBM), and ventral capsule/ventral striatum (VC/VS). While it discusses the regulation of neural networks and neurotransmitter systems as potential mechanisms of DBS action in AD, it does not directly address the use of biomarkers in the prescreening process.

In summary, the use of AD biomarkers in prescreening for DBS remains underdeveloped. Although blood-based biomarkers show promise in identifying AD pathology, their role in DBS candidate selection requires further study. A more comprehensive understanding of DBS's impact on AD pathology, combined with standardized biomarker protocols, may enhance their use in clinical decision-making. However, more research is needed to establish clear guidelines for their application.